SU-GG-T-345: Dose Response and Energy Dependency of Gafchromic EBT2 Film over a Wide Range of Beam Energies and Modalities

The persistence of effects of paclobutrazol or uniconazol on stem elongation was determined for several years after large-leaf Rhododendron and Kalmia latifolia were treated with a single-spray application of these triazol growth-regulator chemicals. Potted plants were treated in the second year from propagation, and transplanted into the field in the following spring. The elongation of stems was measured in the year of application and in the following 2 to 4 years. Treatments with a wide range of doses were applied in 1991, 1992, or 1995. For all except the most-dilute applications, stem elongation was retarded in the year following application. At the highest doses, stem growth was inhibited 2 years following application. The results could be explained by a model of growth regulator action that assumed stem elongation was inversely related to amount of growth regulator applied. The dose response coefficient for paclobutrazol was less than that for uniconazol. The dose that inhibited stem elongation one-half as much as a saturating dose was about 0.5 and 0.05 mg/plant, for paclobutrazol and uniconazol, respectively. The dose response coefficient decreased exponentially with time after application, with an exponential time constant of about 2/year. The model predicted a dose of growth regulator that inhibited 0.9 of stem elongation immediately after application would continue to inhibit 0.5 of stem elongation in the following year.

Download Full-text

Low energy deposition patterns in irradiated phantom with metal artefacts inside: a comparison between FLUKA Monte Carlo simulation and GafChromic EBT2 film measurements

Nuclear Instruments and Methods in Physics Research Section B Beam Interactions with Materials and Atoms ◽

10.1016/j.nimb.2020.06.003 ◽

2020 ◽

Vol 478 ◽

pp. 142-149

Author(s):

Aleksandras Sevcik ◽

Diana Adliene ◽

Jurgita Laurikaitiene ◽

Ruta Nedzinskiene ◽

Ieva Masiulyte

Keyword(s):

Monte Carlo Simulation ◽

Monte Carlo ◽

Energy Deposition ◽

Low Energy ◽

Deposition Patterns ◽

Metal Artefacts ◽

Gafchromic Ebt2 Film ◽

Ebt2 Film

Download Full-text

In vivo biological response to recombinant interferon-gamma during a phase I dose-response trial in patients with metastatic melanoma.

Journal of Clinical Oncology ◽

10.1200/jco.1990.8.6.1070 ◽

1990 ◽

Vol 8 (6) ◽

pp. 1070-1082 ◽

Cited By ~ 13

Author(s):

J M Kirkwood ◽

M S Ernstoff ◽

T Trautman ◽

G Hebert ◽

Y Nishida ◽

...

Keyword(s):

Interferon Gamma ◽

Dose Response ◽

Dose Range ◽

Cell Subset ◽

Optimal Dosage ◽

Antitumor Effects ◽

Ifn Gamma ◽

Recombinant Interferon ◽

Wide Range

Interferon-gamma (IFN gamma), as produced by recombinant DNA technology, has shown a wide range of immunomodulatory activity in vitro and in vivo. Clinical studies have attempted to establish a dose-response relationship to define optimal dosage ranges for induction of effector cell function and host response in patients with cancer. We conducted a randomized trial to test the in vivo biologic activity of five daily dosages ranging from 3 to 3,000 micrograms/m2, administered by daily 2-hour bolus injection or by continuous infusion for 14 days. We demonstrate comparable immunobiologic effects of recombinant IFN gamma (rIFN gamma; Biogen, Inc, Cambridge, MA) administered by these two schedules at the various dosages tested, and have defined a relationship of dose to biologic response over this 3-log10 dose range. Oligo 2'5' adenylate synthetase (2'5'As) induction, natural-killer (NK) cell activity, and T-cell subset distribution (heightened T helper/suppressor ratio) showed the most consistent treatment-associated changes and the greatest immunobiologic effects at dosages of 300 to 1,000 micrograms/m2. Mononuclear cell DR and DQ antigen expression showed no consistent dose-related treatment effect. The relevance of the phenotypic, functional, and enzymologic effects observed in this trial to any clinical antitumor effects of IFN gamma in cancer therapy must now be established.

Download Full-text